TY - JOUR
T1 - QSAR Models for Thyroperoxidase Inhibition and Screening of U.S. and EU Chemical Inventories
AU - Abildgaard Rosenberg, Sine
AU - D. Watt, Eric
AU - Judson, Richard S.
AU - Simmons, S. O.
AU - Paul Friedmann, Katie
AU - Dybdahl, Marianne
AU - Nikolov, Nikolai Georgiev
AU - Wedebye, Eva Bay
N1 - Under a Creative Commons license
PY - 2017
Y1 - 2017
N2 - Thyroperoxidase (TPO) is the enzyme that synthesizes thyroid hormones (THs). TPO inhibition by chemicals can result in decreased TH levels and developmental neurotoxicity, and therefore identification of TPO inhibition is of high relevance in safety evaluation of chemicals. In the present study, we developed two global quantitative structure-activity relationship (QSAR) models for TPO inhibition in vitro. Rigorous cross- and blinded external validations demonstrated that the first model, QSAR1, built from a training set of 877 chemicals, was robust and highly predictive with balanced accuracies of 80.6% (SD = 4.6%) and 85.3%, respectively. The external validation test set was subsequently merged with the training set to constitute a larger training set totaling 1,519 chemicals for a second model, QSAR2, which underwent robust cross-validation with a balanced accuracy of 82.7% (SD = 2.2%). An analysis of QSAR2 identified the ten most discriminating structural features for TPO inhibition and non-inhibition, respectively. Both models were used to screen 72,524 REACH substances and 32,197 U.S. EPA substances, and QSAR2 with the expanded training set had an approximately 10% larger coverages compared to QSAR1. Of the substances predicted within QSAR2’s applicability domain, 8,790 (19.3%) REACH substances and 7,166 (19.0%) U.S. EPA substances, respectively, were predicted to be TPO inhibitors. A case study on butyl hydroxyanisole (BHA), which is extensively used as an antioxidant, was included to exemplify how predictions from the developed QSAR2 model may aid in elucidating the modes of action in adverse outcomes of chemicals. Overall, predictions from QSAR2 can for example be used in priority setting of chemicals and in read-across cases or weight-of-evidence assessments.
AB - Thyroperoxidase (TPO) is the enzyme that synthesizes thyroid hormones (THs). TPO inhibition by chemicals can result in decreased TH levels and developmental neurotoxicity, and therefore identification of TPO inhibition is of high relevance in safety evaluation of chemicals. In the present study, we developed two global quantitative structure-activity relationship (QSAR) models for TPO inhibition in vitro. Rigorous cross- and blinded external validations demonstrated that the first model, QSAR1, built from a training set of 877 chemicals, was robust and highly predictive with balanced accuracies of 80.6% (SD = 4.6%) and 85.3%, respectively. The external validation test set was subsequently merged with the training set to constitute a larger training set totaling 1,519 chemicals for a second model, QSAR2, which underwent robust cross-validation with a balanced accuracy of 82.7% (SD = 2.2%). An analysis of QSAR2 identified the ten most discriminating structural features for TPO inhibition and non-inhibition, respectively. Both models were used to screen 72,524 REACH substances and 32,197 U.S. EPA substances, and QSAR2 with the expanded training set had an approximately 10% larger coverages compared to QSAR1. Of the substances predicted within QSAR2’s applicability domain, 8,790 (19.3%) REACH substances and 7,166 (19.0%) U.S. EPA substances, respectively, were predicted to be TPO inhibitors. A case study on butyl hydroxyanisole (BHA), which is extensively used as an antioxidant, was included to exemplify how predictions from the developed QSAR2 model may aid in elucidating the modes of action in adverse outcomes of chemicals. Overall, predictions from QSAR2 can for example be used in priority setting of chemicals and in read-across cases or weight-of-evidence assessments.
KW - QSAR
KW - Thyroperoxidase (TPO) inhibition
KW - Adverse outcome pathway (AOP)
KW - Screening
KW - BHA
KW - REACH
U2 - 10.1016/j.comtox.2017.07.006
DO - 10.1016/j.comtox.2017.07.006
M3 - Journal article
SN - 2468-1113
VL - 4
SP - 11
EP - 21
JO - Computational Toxicology
JF - Computational Toxicology
ER -